Last update:
Oncology & Cancer news
Medications
GLP-1 medications show little effect on cancer, study shows
A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
12 minutes ago
0
0
Oncology & Cancer
Next-generation CAR T cells show stronger, safer response in animal models
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively killing cancer cells, ...
1 hour ago
0
0
Mobile DNA elements reveal their role in lung cancer progression
Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, ...
4 hours ago
0
0
Real-time imaging captures what happens to cancer cells arriving in the brain
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is ...
5 hours ago
0
0
Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care ...
7 hours ago
0
0
Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
7 hours ago
0
0
Novel endocrine therapy reduces the risk of breast cancer recurrence
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1–3) ...
7 hours ago
0
0
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy ...
7 hours ago
0
0
Cancer signaling discovery reveals potential path to more effective cancer drugs
Interrupting one function of a protein that plays a key role in cell signaling could enable the development of new cancer treatments, according to a study led by Dr. Martin Taylor at the Warren Alpert Medical School of Brown ...
10 hours ago
0
0
A multimodal AI model may improve recurrence risk stratification in early breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, ...
5 hours ago
0
0
FDA approves expanded indication for Jaypirca
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory ...
6 hours ago
0
0
Socioeconomic factors, comorbidities tied to late-onset depression in long-term cancer survivors
Socioeconomic vulnerability and multiple medical comorbidities are risk factors for late-onset depression among long-term cancer survivors, according to a study published in JAMA Network Open.
6 hours ago
0
0
New gene-mapping method unlocks hidden drivers of cancer
University of South Australia scientists have developed a powerful new way to uncover the genetic interactions that fuel cancer progression, paving the way for earlier and more precise treatments.
20 hours ago
0
12
Combination treatment shows large improvement in survival for people with relapsed myeloma
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded ...
20 hours ago
0
1
Enhancing breast cancer screening could help save young women's lives
In Estonia, breast cancer screening is offered from the age of 50, yet one-fifth of first diagnoses occur in younger women. A new clinical study has therefore been conducted to test better ways to detect the disease early.
18 hours ago
0
0
Study reveals online support lacking for sarcoma patients and their caregivers
A new Curtin University study has found that people diagnosed with sarcoma—a cancer disproportionately affecting teenagers and young adults—are being left without the resources they urgently need.
18 hours ago
0
0
Drug resistance in pancreatic cancer: Scientists pinpoint major and minor signaling pathways that drive it
Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites seeding new resistant tumors elsewhere in the body.
Disarming cancer stem cells' shield makes immunotherapy more effective
Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, it works very well in shrinking tumors and sending cancer into remission, an undetectable state of ...
Dec 9, 2025
0
0
Ultrasensitive liquid biopsy method detects low-frequency cancer mutations
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA circulating in the blood.
Dec 9, 2025
0
13
Team discovers how to target 'undruggable' protein that fuels aggressive leukemia
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a small molecule that can inhibit a cancer-driving protein long considered impossible to target with drugs—a discovery that could open the ...
Dec 9, 2025
0
0
Tec-Dara combination offers improvement over standard second-line therapies for relapsed, refractory multiple myeloma
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive ...
Dec 9, 2025
0
0
Next-gen CAR-T cell therapy shows early promise in patients with refractory B-cell acute lymphoblastic leukemia
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using the T-Charge platform, ...
Dec 9, 2025
0
0
Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
Dec 9, 2025
0
0
Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in angioimmunoblastic T cell lymphoma (AITL), a type of nodal T cell lymphoma, and identified overexpression ...
Dec 9, 2025
0
0
New data highlight promise of pivekimab sunirine in two aggressive blood cancers
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive ...
Dec 9, 2025
0
0
